Healthy Volunteer Study

A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of D-2570 Tablets in Healthy Subjects

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07270783

Enrollment

Registered

2025-12-08

Start date

2025-12-04

Completion date

2026-09-01

Last updated

2026-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteer

Brief summary

Double Blinded Healthy Volunteer study evaluating D-2570 against placebo in various doses.

Detailed description

Double blind study evaluating the safety, tolerability and PK data of D-2570/placebo in healthy volunteers.

Interventions

DRUGD-2570

D-2570

DRUGPlacebo

Placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy volunteer subjects meeting eligibility criteria

Exclusion criteria

* Subjects with ongoing or history of disease or co-morbidities as assessed by Principal Investigator which would make them ineligible for the study * Subjects with a history of drug and alcohol abuse * Subjects taking medications, over the counter or herbal remedies

Design outcomes

Primary

Measure	Time frame	Description
Incidence of adverse events	From Informed Consent through study completion, an average of 48 days	Incidence of adverse events
Result of Pharmacokinetic endpoint	From Randomization through study completion, an average of 20 days	Tmax

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 15, 2026